Filing Flows › Comparisons › ALLR vs IBO
Allarity Therapeutics vs Impact Biomedical: ALLR and IBO compared
Allarity Therapeutics is the larger company: $25K of revenue in its latest quarter (Q1 2026) against $21K for Impact Biomedical (Q3 2026).
Where the money goes: ALLR and IBO
Allarity Therapeutics (ALLR) · Q1 2026
Allarity Therapeutics, Q1 2026: revenue $25K, net loss $2.8M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Impact Biomedical (IBO) · Q3 2026
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart follows the revenue to costs, profit and cash.
| Allarity Therapeutics (ALLR) | Impact Biomedical (IBO) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q3 2026 |
| Revenue | $25K | $21K |
| Revenue growth, Y/Y | — | +17% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.8M | −$644K |
| Operating cash flow | −$4.5M | $11K |
Questions
Which is bigger, Allarity Therapeutics or Impact Biomedical?
Allarity Therapeutics is the larger company: $25K of revenue in its latest quarter (Q1 2026) against $21K for Impact Biomedical (Q3 2026).
More: Allarity Therapeutics earnings · how Allarity Therapeutics makes money · Impact Biomedical earnings · how Impact Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 15, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.